UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 30, 2023

 

BIONEXUS GENE LAB CORP.

(Exact name of Company as specified in charter)

 

Wyoming

333-229399

35-2604830

(State or another jurisdiction

of incorporation)

(Commission

File No.)

(IRS Employer

Identification No.)

 

Unit 2, Level 10, Tower B, Avenue 3

The Vertical Business Suite II Bangar South

No. 8 Jalan Kerinchi

Kuala Lumpur, Malaysia, 59200

(Address of Principal Executive Offices) (Zip code)

 

+60 1221-26512

(Company’s Telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, no par value

 

BGLC

 

Nasdaq Capital Market

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Departure of Wei Li Leong as Chief Financial Officer.

 

On October 30, 2023, Ms. Wei Li Leong, the Chief Financial Officer (“CFO”), tendered her resignation letter to BioNexus Gene Lab Corp. (the “Company”) from her position at the Company. The Company and Ms. Leong agreed that the resignation would be effective October 30, 2023 (“Resignation Date”), and Ms. Leong agreed to continue serving for one additional month from the Resignation Date. Ms. Leong’s resignation is not due to any disagreement with the Company, the Company’s management, or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise).

 

The Company will actively identify a replacement personnel. The Company believes that it will be able to appoint a new CFO in the near future.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BIONEXUS GENE LAB CORP

 

 

 

 

Date: November 3, 2023

By:

/s/ Chi Yuen Leong

 

 

Name:

Chi Yuen Leong

 

 

Title:

Chief Executive Officer

 

 

 

3

v3.23.3
Cover
Oct. 30, 2023
Cover [Abstract]  
Entity Registrant Name BIONEXUS GENE LAB CORP.
Entity Central Index Key 0001737523
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Oct. 30, 2023
Entity Ex Transition Period false
Entity File Number 333-229399
Entity Incorporation State Country Code WY
Entity Tax Identification Number 35-2604830
Entity Address Address Line 1 Unit 2, Level 10, Tower B, Avenue 3
Entity Address Address Line 2 The Vertical Business Suite II Bangar South
Entity Address Address Line 3 No. 8 Jalan Kerinchi
Entity Address City Or Town Kuala Lumpur
Entity Address Postal Zip Code 59200
City Area Code 60
Local Phone Number 1221-26512
Security 12b Title Common Stock, no par value
Trading Symbol BGLC
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
BioNexus Gene Lab (NASDAQ:BGLC)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more BioNexus Gene Lab Charts.
BioNexus Gene Lab (NASDAQ:BGLC)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more BioNexus Gene Lab Charts.